FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

CADILAHC

604
+2.25 (0.37%)
Updated 03:29 07/05 IST

CADILAHC Buy or Sell - FrontPage Forums

15 Users have submitted 16 trade ideas of Rs. 2,121,775.65 for CADILAHC
Disclaimer
100% Bullish
0% Bearish

CADILAHC Buy or Sell - Brokerage Reports

No. of reports in last year
6
No. of analysts
4
Average Consensus Forecast
437.67
Consensus Potential
-46.34%
See CADILAHC Share Price Targets >>

CADILAHC Ratings

Long term CADILAHC rating by FrontPage users
4.3/5 (7 Ratings)
Find answers to all your questions on live CADILAHC message board: Is CADILAHC buy or sell? Should I buy CADILAHC shares? Why are CADILAHC shares falling? Should I invest in CADILAHC stock?

  1. Home
  2. CADILAHC Forum

CADILAHC Share Price Discussion

N
Reputation: 13,650 • May 7 5:21 AM
How Indian pharma companies should have dealt with Remdesivir crisis
Incidentally, pharma companies have been conspicuous by their silence, busy making hay while the sun shines. Except for disseminating helpline numbers or web-links to check the availability of the medicine stock — measures that havent helped much during the peak of the second wave —the companies did little to stem the crisis. Instead, they became part of the problem as they faltered in their role of patients outreach and doctor education.
The Economic Times
Like
Reply
H
Reputation: 48 • May 7 6:55 AM

Type
Buy
Instrument
CADILAHC
Entry Price
₹602
Price@Trade
₹603.1
Target Price
₹1,000
Stop Price
₹500
Valid Till
Jun 7, 2021 3:20 AM
Margin
₹602,000 approx for 1000 Qty
Status
Exited before entry
Like
Reply (1)
swap_vert
Trade
See all replies
Haritha @Haritha312
May 7 7:02 AM

Update
Exited before entry
Price @ Update
₹602.6

Type
Buy
Instrument
CADILAHC MAY21 FUT
Entry Price
₹610
Price@Trade
₹609.55
Target Price
₹640
Stop Price
₹595
Valid Till
May 27, 2021 3:20 AM
Margin
₹323,044.15 approx for 2200 Qty
Status
Active
Like
Reply (3)
swap_vert
Trade
See all replies
Surya @surya-BJ8AkWbfd
May 7 5:58 AM

Update
Entry Price Modified
Price @ Update
₹609.7
Original Entry Price
₹610
New Entry Price
₹609.7
Surya @surya-BJ8AkWbfd
May 7 5:58 AM

Update
Entry Price Modified
Price @ Update
₹610
Original Entry Price
₹609.7
New Entry Price
₹610
TrackerBot @trackerbot
May 7 5:59 AM

Update
Trade Entered
Entry Price
₹610
C
Reputation: 1,613 • May 7 5:52 AM
Like
Reply

Type
Sell
Instrument
CADILAHC
Entry Price
₹606.5
Price@Trade
₹606.5
Target Price
₹602
Stop Price
₹610
Valid Till
May 7, 2021 3:20 AM
Margin
₹60,650 approx for 100 Qty
Status
Stoploss Hit
Exit Price
₹610
Net P&L
-₹350 (-0.58%)
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
May 7 5:44 AM

Update
Stoploss Hit
Exit Price
₹610

Type
Buy
Instrument
CADILAHC MAY21 600 CE
Entry Price
₹33.25
Price@Trade
₹33.2
Target Price
₹65
Stop Price
₹29
Valid Till
May 27, 2021 3:20 AM
Margin
₹73,150 approx for 2200 Qty
Status
Active
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
May 7 4:09 AM

Update
Trade Entered
Entry Price
₹33.25
N
Reputation: 2,217 • May 7 3:41 AM

Type
Buy
Instrument
CADILAHC MAY21 670 CE
Entry Price
₹11.65
Price@Trade
₹11.65
Target Price
₹20
Stop Price
₹4.95
Valid Till
May 7, 2021 3:20 AM
Margin
₹25,630 approx for 2200 Qty
Status
Exited
Exit Price
₹11.2
Net P&L
-₹990 (-3.86%)
Like
Reply (1)
swap_vert
Trade
See all replies
Nifty King @niftyking
May 7 5:42 AM

Update
Exited
Exit Price
₹11.2
Net P&L
-₹990 (-3.86%)

Bought #CADILAHC options - CADILAHC21MAY640CE at 19.30
Like
Reply

Type
Buy
Instrument
CADILAHC MAY21 600 CE
Entry Price
₹37  ₹33
Price@Trade
₹34.55
Target Price
₹70
Stop Price
₹30
Valid Till
May 27, 2021 3:20 AM
Margin
₹72,600 approx for 2200 Qty
Status
Active
Like
Reply (4)
swap_vert
Trade
See all replies
Abhijit @abhijit-r1M-Z10NO
May 7 8:04 AM

Update
Entry Price Modified
Price @ Update
₹31.75
Original Entry Price
₹32
New Entry Price
34.0
Abhijit @abhijit-r1M-Z10NO
May 7 8:25 AM

Update
Entry Price Modified
Price @ Update
₹32.2
Original Entry Price
₹34
New Entry Price
33.0
TrackerBot @trackerbot
May 7 8:36 AM

Update
Trade Entered
Entry Price
₹33

Type
Buy
Instrument
CADILAHC
Entry Price
₹607  ₹607.65
Price@Trade
₹607.4
Target Price
₹620
Stop Price
₹600
Valid Till
May 10, 2021 3:20 AM
Margin
₹60,765 approx for 100 Qty
Status
Active
Like
Reply (2)
swap_vert
Trade
See all replies
Abdul Salman @abdulsalman
May 7 3:35 AM

Update
Entry Price Modified
Price @ Update
₹607.65
Original Entry Price
₹607
New Entry Price
₹607.65
TrackerBot @trackerbot
May 7 3:35 AM

Update
Trade Entered
Entry Price
₹607.65
Q. What is view for tomorrow in cadila?
1
Reply (1)
See all replies
Nifty King @niftyking
May 7 2:29 AM

Very bullish

Type
Buy
Instrument
CADILAHC MAY21 600 CE
Entry Price
₹32.35
Price@Trade
₹32.35
Target Price
₹40
Stop Price
₹30
Valid Till
May 7, 2021 3:20 AM
Margin
₹71,170 approx for 2200 Qty
Status
Stoploss Hit
Exit Price
₹30
Net P&L
-₹5,170 (-7.26%)
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
May 7 2:48 AM

Update
Stoploss Hit
Exit Price
₹30
T
Reputation: 3,975 • May 6 8:43 AM

Type
Buy
Instrument
CADILAHC MAY21 FUT
Entry Price
₹605.95
Price@Trade
₹605.95
Target Price
₹710
Stop Price
₹565  ₹605.5
Valid Till
May 27, 2021 3:20 AM
Margin
₹296,050.15 approx for 2200 Qty
Status
Stoploss Hit
Exit Price
₹605.5
Net P&L
-₹990 (-0.33%)
Like
Reply (2)
swap_vert
Trade
See all replies
TRADE WITH TREND ⚡ @TWT
May 6 8:52 AM

Update
Stoploss Trailed
Price @ Update
₹605.65
Original SL
₹565
New SL
₹605.5
TrackerBot @trackerbot
May 6 8:53 AM

Update
Stoploss Hit
Exit Price
₹605.5

Type
Buy
Instrument
CADILAHC MAY21 600 CE
Entry Price
₹31.5
Price@Trade
₹31.65
Target Price
₹50
Stop Price
₹25
Valid Till
May 27, 2021 3:20 AM
Margin
₹69,300 approx for 2200 Qty
Status
Exited
Exit Price
₹34.45
Net P&L
+₹6,490 (+9.37%)
Like
Reply (3)
swap_vert
Trade
See all replies
Surya @surya-BJ8AkWbfd
May 6 8:37 AM

Update
Entry Price Modified
Price @ Update
₹31.5
Original Entry Price
₹31.5
New Entry Price
₹31.5
TrackerBot @trackerbot
May 6 8:37 AM

Update
Trade Entered
Entry Price
₹31.5
Surya @surya-BJ8AkWbfd
May 7 5:22 AM

Update
Exited
Exit Price
₹34.45
Net P&L
+₹6,490 (+9.37%)
Like
Reply
B
Reputation: 0 • May 6 7:15 AM

Type
Buy
Instrument
CADILAHC
Entry Price
₹600
Price@Trade
₹596.1
Target Price
₹608
Stop Price
₹596
Valid Till
May 6, 2021 3:20 AM
Margin
₹60,000 approx for 100 Qty
Status
Validity Over
Exit Price
₹600.85
Net P&L
+₹85 (+0.14%)
Like
Reply (2)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
May 6 8:26 AM

Update
Trade Entered
Entry Price
₹600
TrackerBot @trackerbot
May 6 8:51 AM

Update
Validity Over
Exit Price
₹600.85
Net P&L
+₹85 (+0.14%)

Type
Buy
Instrument
CADILAHC
Entry Price
₹595.3
Price@Trade
₹595.3
Target Price
₹645.25
Stop Price
₹558.9
Valid Till
May 14, 2021 3:20 AM
Margin
₹59,530 approx for 100 Qty
Status
Exited
Exit Price
₹602.7
Net P&L
+₹740 (+1.24%)
Like
Reply (1)
swap_vert
Trade
See all replies
Anupam Dutta @duttaanupam
May 6 8:43 AM

Update
Exited
Exit Price
₹602.7
Net P&L
+₹740 (+1.24%)
Like
Reply
Like
Reply

Type
Buy
Instrument
CADILAHC MAY21 FUT
Entry Price
₹599  ₹599.05
Price@Trade
₹599.2
Target Price
₹1,000
Stop Price
₹200
Valid Till
May 27, 2021 3:20 AM
Margin
₹296,201.95 approx for 2200 Qty
Status
Exited
Exit Price
₹599.6
Net P&L
+₹1,210 (+0.41%)
Like
Reply (3)
swap_vert
Trade
See all replies
ROHIT JAIN @jainrohit22
May 6 5:52 AM

Update
Entry Price Modified
Price @ Update
₹599.05
Original Entry Price
₹599
New Entry Price
₹599.05
TrackerBot @trackerbot
May 6 5:53 AM

Update
Trade Entered
Entry Price
₹599.05
ROHIT JAIN @jainrohit22
May 6 5:56 AM

Update
Exited
Exit Price
₹599.6
Net P&L
+₹1,210 (+0.41%)
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 2,00,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • CADILAHC - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization35,491.84
    Enterprise Value38,320.54
    Price to Earnings35.57
    Price to Book Value3.96
    Return on Capital Employed0.15
    Return on Equity0.14
    Face Value1
    Dividend Yield0.01
  • CADILAHC - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    2-Mar-21Nirmal BangAccumulate470
    8-Feb-21Prabhudas LilladherAccumulate522
    8-Feb-21Dolat CapitalAccumulate503
    7-Nov-20Geojit Financial ServicesBuy511
    3-Nov-20Prabhudas LilladherSell357
    CADILAHC Brokerage Price Target
  • CADILAHC Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    May 7603.85611.9599603.2
    May 6607.95610.85592.65601.75
    May 5571.05607.75565.5601.7
    May 4587587.95566.05569.15
    May 3574.95584.5570.45580.8
  • CADILAHC Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹549.92
    30 Day Moving Average₹512.54
    50 Day Moving Average₹482.9
    100 Day Moving Average₹478.82
    200 Day Moving Average₹440.15
  • CADILAHC - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue5,8093,230.70.8
    Operating Profit1,646321.14.13
    Profit Before Tax1,497642.21.33
    Net Income1,090661.90.65
  • CADILAHC - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds8,9567,7450.16
    Total Liabilities4,5364,4840.01
    Total Assets13,49212,2300.1
  • CADILAHC - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity2891,291.9-0.78
    Cash from Investing Activity26-2,904.5-1.01
    Cash from Financing Activity-1481,365.6-1.11
    Net Cash Flow167-247-1.68
  • CADILAHC - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.090.06
    Return on Equity0.140.1
    Return on Capital Employed0.150.07
  • CADILAHC - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.1
    3 Year CAGR Growth in Operating Profit0.07
    3 Year CAGR Growth in EBIDTA0.08
    3 Year CAGR Growth in Net Income-0.14
    3 Yr CAGR Growth - Diluted EPS-0.83
  • CADILAHC - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.65
    5 Year CAGR Growth in Operating Profit1.33
    5 Year CAGR Growth in EBIDTA1.44
    5 Year CAGR Growth in Net Income1.19
    3 Yr CAGR Growth - Diluted EPS-0.56
  • CADILAHC - Recent News

    keyboard_arrow_down
    NewsBot
    May 7 5:21 AM
    How Indian pharma companies should have dealt with Remdesivir crisis
    The Economic Times
    NewsBot
    May 3 7:31 AM
    PIL in HC seeks all Remdesivir makers be allowed to sell it in domestic market
    The Economic Times
    NewsBot
    May 1 6:06 AM
    Crisis over shortage of Remdesivir, Fabiflu to end by next fortnight
    The Economic Times
    NewsBot
    Apr 27 7:06 AM
    Gilead to expand remdesivir availability in India; donate 4.5 lakh vials to govt
    The Economic Times
    NewsBot
    Apr 26 4:56 AM
    Cadila best bet in midcap pharma; expect decent result from Reliance: Sandip Sabharwal
    The Economic Times
    NewsBot
    Apr 26 1:56 AM
    UP government orders 50 lakh doses of Covisheild, Covaxin each
    The Economic Times
    NewsBot
    Apr 23 8:56 AM
    Zydus gets emergency nod for Pegylated Interferon alpha-2b, ‘Virafin’ for COVID-19 treatment in adults
    The Economic Times
    NewsBot
    Apr 21 6:31 AM
    Customs duty waive off on Remdesivir will further augment domestic availability: Sadanand Gowda
    The Economic Times
    NewsBot
    Apr 21 12:51 PM
    Vaccine manufacturers frame plans to boost production
    The Economic Times
    NewsBot
    Apr 20 5:21 AM
    Is it time to buy HDFC Bank once again? Deven Choksey answers
    The Economic Times
  • CADILAHC - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Apollo Hospitals Enterprise Ltd. NSE:...
  • CADILAHC - More Information

    keyboard_arrow_down

    Cadila HealthcareLtd:
    Cadila Healthcare Limited is associated with researching, producing, developing, marketing and distributing pharmaceutical products in India and several other countries like Spain, South Africa, France as well as Latin American countries. It offers a wide range of products, including wellness products, active pharmaceutical ingredients, human dosage formulations, vaccines, animal healthcare products, and biosimilars.
    Apart from this, the company offers several other products in various medical aspects of pain-management, gastrointestinal therapy, gynaecology, dermatology, respiratory issues, etc. Among some of its famous products are, Glucon-D (glucose power, EverYuth in their skincare products range, Sugar-Free and Nycil (prickly heat talc).
    Additionally, Cadila has ongoing development of 21 biosimilars along with six different novel products. It also has drugs in multiple aspects for treatment of autoimmune diseases, cancer, diseases concerned with ophthalmology, hepatology, nephrology, rheumatology and several infectious diseases. It also associates itself with retail pharmacy, labour supply along with administration activities. Cadila is an Ahmedabad based company in India and was incorporated back in 1952.
    About Company Information:
    In 1996, Cadila Healthcare Ltd launched Falcigo through a strategic alliance agreement with a China-based company named Gulin Pharma. In MAY, 2000 Cadila had a helping hand for strengthening its southern market by acquiring Recon Ltd. In the following year, the company acquired German Remedies. This newly acquired company was the top M&A company in the pharmaceutical sector in India.
    In the same year, 2001, Cadila entered into an alliance with Oncova with the aim of running research together in the aspect of Oncogenomics. The next year, in 2002, the company went on to acquire Banyan Chemicals. In the following year, in 2003, Zydus Pathline, German Remedies, Zoom Properties and Recon Healthcare, all of them merged with Cadila Healthcare Ltd.
    In 2005, Cadila Healthcare Ltd. entered into a strategic agreement with Mallinckrodt Pharmaceuticals Generics. This was a strategic alliance for marketing products launched by Mallinckrodt through one of their business units, under a single joint label.In 2005 itself, the company wished to cater to international needs by manufacturing active pharmaceutical ingredients and cytotoxic drugs along with injectables, for this purpose it signed a fifty-fifty joint agreement with Mayne Pharma, an Australia based company.
    During 2005-2006 the company signed an agreement with Bharat Serums and Vaccines Ltd. These two companies came together to form Zydus BSV Pharma Private Limited for developing, manufacturing and marketing proprietary Novel Drug Delivery System that would sell anti-cancer goods in international markets.
    During 2007-2008, Cadila launched two new divisions, namely, Fortiza and Corza, while focusing on restructuring their existing Alidac division. In February of 2008, in the aspect of research in drug discovery and their development, Cadila went into a 3-year contract with a Swedish company Karo Bio.
    On the 28th of January in 2011, Bayer Healthcare had signed an agreement with Cadila for setting up Bayer Zydus Pharma which will be responsible for selling pharmaceutical products in India. Each of these two companies entering the alliance were to hold 50 of shares each and have equal representation on the board, Bayer Zydus was headquartered in Mumbai.
    On 25th of July, 2013, Cadila along with a non-profit organization based in Seattle, named IDRI, declared that these two organizations would collaborate for clinical development of IDRI’s VL vaccine for attacking parasites. It was also agreed upon that Cadila would also be responsible for producing this product.
    On the 31st of December, 2015, the company informed that the USFDA sent a letter of warning for the company’s Ahmedabad active pharmaceutical ingredients facility and its Moraiya formulation. In February of 2016, the company informed that it was permitted by the USFDA for marketing Doxycycline Capsules USP, 100 mg, 50 mg, and 75 mg.
    On the 28th of March, 2016, Cadila announced that its subsidiary company Zydus was all set to acquire Actibile from a company named Albert David Ltd. This brand of the drug is for gastroenterology aspect and also used for treating stones in the gallbladder.
    How Cadila HealthcareLtd, is categorised as a Pharmaceutical and Healthcare Sector, and Pharmaceutical Industry :
    The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Cadila Healthcare Ltd is categorized under the Health care sector and Hospitals and Medical services Industry. Healthcare sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more.
    The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Cadila HealthcareLtd, Competitors and Sector Peers:
    Aarey Drugs & Pharmaceuticals Ltd. AARDRU
    Aarti Drugs Ltd. AARTDR
    Aayush Food & Herbs Ltd. AAYFOO
    Abbott India Ltd. ABBIND
    ABL Bio-Technologies Ltd. ABLBIO
    Addlife Pharma Ltd. ADDPHA
    Bacil Pharma Ltd. BACPHA
    Bafna Pharmaceuticals Ltd. BAFPHA
    Bajaj Healthcare Ltd. BAJHEA
    Brooks Laboratories Ltd. BROLAB
    Cipla Ltd. CIPLTD
    Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
    Divi's Laboratories Ltd. DIVIL
    Dr. Reddy's Laboratories Ltd. DR
    Dujohn Laboratories Ltd. DUJLAB
    Earum Pharmaceuticals Ltd.
    Elder Health Care Ltd. ELDHEA
    Elder Pharmaceuticals Ltd. ELDPHA
    Elegant Pharmaceuticals Ltd. ELEPHA
    Gennex Laboratories Ltd. GENLAB
    Genomics Biotech Ltd. GENBIO
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    JK Pharmachem Ltd. JKPHAL
    Jubilant Life Sciences Ltd. JUBILO
    Jupiter Bioscience Ltd. JUPIBI
    Lupin Ltd. LUPLTD
    Lyka Labs Ltd. LYKLAB
    Novartis India Ltd. NOVAIN
    Ortin Laboratories Ltd. ORTLAB
    Piramal Enterprises Ltd. NICPIR
    Piramal Phytocare Ltd. PIRLIF
    Ranbaxy Laboratories Ltd. RANLAB
    Sanjivani paranteral Ltd. SANPAR
    Sanofi India Ltd. AVEPHA
    Sarvodaya Labs Ltd. SARLAB
    Sun Pharmaceutical Industries Ltd. SUN28
    TTK Healthcare Ltd. TTKHEA
    Venmax Drugs & Pharmaceuticals Ltd. YENDRU
    Venus Remedies Ltd. VENREM
    Zenith Healthcare Ltd. ZENHEA
    Zenlabs Ethica Ltd. SHRLAK
    Zenotech Laboratories Ltd. ZENLAB
    Zim Laboratories Ltd. ZIMLAB
    Zora Pharma Ltd.[Amalgamated] ZORPHA
    Zota Healthcare Ltd. ZOTHEA
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020